mr. kranda said immunex met goal break
even 1991 expect announc modest profit
fourth quarter full year elabor
analyst expect compani report
earn $ 500,000 four cent share 1991
final result due februari
mr. kranda said immunex plan increas r spend
50 % $ 45 million 1992 focus clinic
develop blood-cel growth factor receptor
product treat inflamm wast
invest depress 1992 earn per share
current consensus estim wall street analyst
execut said forecast averag 85 cent
share rang high $ 2.50 share
